Fintel reports that on May 6, 2026, Canaccord Genuity initiated coverage of Kymera Therapeutics (NasdaqGM:KYMR) with a Buy recommendation.
Analyst Price Forecast Suggests 46.57% Upside
As of April 28, 2026, the average one-year price target for Kymera Therapeutics is $121.23/share. The forecasts range from a low of $91.91 to a high of $147.00. The average price target represents an increase of 46.57% from its latest reported closing price of $82.71 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Kymera Therapeutics is 99MM, an increase of 92.10%. The projected annual non-GAAP EPS is -2.89.
What is the Fund Sentiment?
There are 270 funds or institutions reporting positions in Kymera Therapeutics. This is an decrease of 141 owner(s) or 34.31% in the last quarter. Average portfolio weight of all funds dedicated to KYMR is 0.35%, an increase of 14.66%. Total shares owned by institutions increased in the last three months by 1.92% to 89,280K shares. 
The put/call ratio of KYMR is 1.46, indicating a bearish outlook.
What are Other Shareholders Doing?
Baker Bros. Advisors holds 8,657K shares representing 10.52% ownership of the company. In its prior filing, the firm reported owning 6,651K shares , representing an increase of 23.17%. The firm increased its portfolio allocation in KYMR by 44.99% over the last quarter.
Avoro Capital Advisors holds 7,475K shares representing 9.09% ownership of the company. In its prior filing, the firm reported owning 6,350K shares , representing an increase of 15.05%. The firm increased its portfolio allocation in KYMR by 23.05% over the last quarter.
Price T Rowe Associates holds 6,159K shares representing 7.49% ownership of the company. In its prior filing, the firm reported owning 5,097K shares , representing an increase of 17.24%. The firm decreased its portfolio allocation in KYMR by 14.78% over the last quarter.
Bvf holds 5,503K shares representing 6.69% ownership of the company. No change in the last quarter.
Atlas Venture Life Science Advisors holds 4,660K shares representing 5.66% ownership of the company. In its prior filing, the firm reported owning 4,896K shares , representing a decrease of 5.08%.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
